IDEXX Laboratories, Inc. $IDXX Shares Sold by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,800 shares of the company’s stock after selling 15,300 shares during the period. Factory Mutual Insurance Co. owned 0.06% of IDEXX Laboratories worth $29,261,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in IDXX. ICICI Prudential Asset Management Co Ltd increased its position in IDEXX Laboratories by 21.9% in the third quarter. ICICI Prudential Asset Management Co Ltd now owns 1,228 shares of the company’s stock worth $785,000 after buying an additional 221 shares during the period. Wealth Alliance LLC increased its position in shares of IDEXX Laboratories by 6.1% during the 3rd quarter. Wealth Alliance LLC now owns 747 shares of the company’s stock valued at $477,000 after purchasing an additional 43 shares during the period. Avestar Capital LLC raised its position in IDEXX Laboratories by 43.8% in the third quarter. Avestar Capital LLC now owns 919 shares of the company’s stock worth $587,000 after acquiring an additional 280 shares in the last quarter. Essex Financial Services Inc. raised its holdings in shares of IDEXX Laboratories by 1.9% in the 3rd quarter. Essex Financial Services Inc. now owns 1,494 shares of the company’s stock worth $955,000 after purchasing an additional 28 shares in the last quarter. Finally, Syon Capital LLC increased its holdings in shares of IDEXX Laboratories by 11.3% in the third quarter. Syon Capital LLC now owns 1,016 shares of the company’s stock valued at $649,000 after buying an additional 103 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Morgan Stanley lifted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Performance

IDXX stock opened at $630.73 on Friday. The firm has a 50 day simple moving average of $679.11 and a 200 day simple moving average of $669.15. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The stock has a market cap of $50.36 billion, a P/E ratio of 48.26, a P/E/G ratio of 3.86 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director owned 648 shares of the company’s stock, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 18,180 shares of company stock valued at $11,626,996. 0.98% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.